Seres Therapeutics/$MCRB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Seres Therapeutics
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
Ticker
$MCRB
Sector
Primary listing
Employees
66
Headquarters
Website
MCRB Metrics
BasicAdvanced
$83M
13.55
$0.64
0.29
-
Price and volume
Market cap
$83M
Beta
0.29
52-week high
$29.98
52-week low
$6.53
Average daily volume
84K
Financial strength
Current ratio
2.555
Quick ratio
2.395
Long term debt to equity
164.132
Total debt to equity
187.629
Profitability
EBITDA (TTM)
-89.838
Gross margin (TTM)
-6,947.40%
Net profit margin (TTM)
721.93%
Operating margin (TTM)
-11,910.14%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-42.25%
Return on equity (TTM)
19.64%
Valuation
Price to earnings (TTM)
13.547
Price to revenue (TTM)
97.348
Price to book
1.87
Price to tangible book (TTM)
1.87
Price to free cash flow (TTM)
88.795
Free cash flow yield (TTM)
1.13%
Free cash flow per share (TTM)
0.098
Growth
Earnings per share change (TTM)
14,333.92%
3-year earnings per share growth (CAGR)
-76.00%
10-year earnings per share growth (CAGR)
-34.86%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Seres Therapeutics stock?
Seres Therapeutics (MCRB) has a market cap of $83M as of March 24, 2026.
What is the P/E ratio for Seres Therapeutics stock?
The price to earnings (P/E) ratio for Seres Therapeutics (MCRB) stock is 13.55 as of March 24, 2026.
Does Seres Therapeutics stock pay dividends?
No, Seres Therapeutics (MCRB) stock does not pay dividends to its shareholders as of March 24, 2026.
When is the next Seres Therapeutics dividend payment date?
Seres Therapeutics (MCRB) stock does not pay dividends to its shareholders.
What is the beta indicator for Seres Therapeutics?
Seres Therapeutics (MCRB) has a beta rating of 0.29. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.